Evidence of a role of tumor necrosis factor alpha in refractory asthma.

By M. Berry, B. Hargadon, M. Shelley, D. Parker, D. Shaw, R. Green, P. Bradding, C. Brightling, A. Wardlaw, I. Pavord. New England Journal of Medicine, 2006

848 citations recorded by the source corpus.

Subfields: Immunology, Physiology, Sociology and Political Science

View Paper: https://www.semanticscholar.org/paper/570f15ca05a418b6f3397883741a5f4346fbfdba

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. P. Barnes
2. J. Fahy
3. Steven F. Ziegler
4. J. Arron
5. J. Bradley
6. S. Holgate
7. Riccardo Polosa
8. Sally E. Wenzel

In Physiology

1. P. Barnes
2. J. Fahy
3. Sally E. Wenzel
4. Ian M. Adcock
5. J. Arron
6. S. Holgate
7. Riccardo Polosa

In Sociology and Political Science

1. Sally E. Wenzel
2. P. Barnes

Citations in the corpus

• Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells (2007, background): “Given the important role of TNF in severe asthma (18), it is of note that this cytokine was released at high levels by MCs stimulated with IL-1 and TSLP (not depicted).”
• The cytokine network in asthma and chronic obstructive pulmonary disease. (2008, background): “Blocking TNF-α with etanercept (a fusion protein comprising human soluble TNFR linked to the Fc component of human IgG1) reduced AHR and improved lung function in a small study of patients with refractory asthma (52).”
• TNF‐mediated inflammatory disease (2008, background): “A pilot study of patients with refractory asthma provided evidence for a role of TNF, and demonstrated a beneficial effects of etanercept on markers of asthma control [138].”
• International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma (2013, background): “recent genomic and proteomic approaches have suggested increases in IL-1β in certain asthmatics, in conjunction with neutrophilia [107-109].”
• Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “In these cases, a marked increase in TNF production has been observed (Berry et al., 2006).”
• Treatment strategies for allergy and asthma (2008, background): “in severe asthma, two small studies have reported the efficacy of the soluble TNF-receptor fusion protein etanercep”
• T-helper type 2-driven inflammation defines major subphenotypes of asthma. (2009, background): “TNF-a is not considered a Th2 cytokine, but it has been previously associated with severe asthma (32).”